US20110065096A1 - Viral diagnostic method and well for use in same - Google Patents
Viral diagnostic method and well for use in same Download PDFInfo
- Publication number
- US20110065096A1 US20110065096A1 US12/947,181 US94718110A US2011065096A1 US 20110065096 A1 US20110065096 A1 US 20110065096A1 US 94718110 A US94718110 A US 94718110A US 2011065096 A1 US2011065096 A1 US 2011065096A1
- Authority
- US
- United States
- Prior art keywords
- well
- virus
- wells
- cell line
- single flat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003612 virological effect Effects 0.000 title abstract description 15
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 82
- 102000004190 Enzymes Human genes 0.000 claims abstract description 16
- 108090000790 Enzymes Proteins 0.000 claims abstract description 16
- 229940088597 hormone Drugs 0.000 claims abstract description 16
- 239000005556 hormone Substances 0.000 claims abstract description 16
- 241000700605 Viruses Species 0.000 claims description 91
- 239000002609 medium Substances 0.000 claims description 24
- 238000011084 recovery Methods 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 239000006143 cell culture medium Substances 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000002203 pretreatment Methods 0.000 claims description 5
- 239000005723 virus inoculator Substances 0.000 claims description 4
- 238000007373 indentation Methods 0.000 claims description 2
- 239000003104 tissue culture media Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 73
- 239000000523 sample Substances 0.000 description 28
- 230000000120 cytopathologic effect Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 241000709661 Enterovirus Species 0.000 description 12
- 241000700584 Simplexvirus Species 0.000 description 8
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000005499 meniscus Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229960001322 trypsin Drugs 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002338 cryopreservative effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000008518 non respiratory effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 1
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
- -1 D-glucose Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50855—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates using modular assemblies of strips or of individual wells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N21/03—Cuvette constructions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
- B01L2300/0851—Bottom walls
Definitions
- the present invention relates to a single flat-based well suitable for use in a viral diagnostic method. More particularly, the well has a planar or flat base, as opposed to a curved base.
- the invention also relates to a viral diagnostic method that employs such single wells. In an embodiment of this method a specially developed tissue culture medium supplemented with hormones and enzymes is employed.
- Conventional diagnostic procedures for identifying viruses include seeding containers with particular cell lines selected on their sensitivity to certain viruses and then inoculating the cell culture with a biological sample putatively containing a virus.
- biological samples include among other things saliva, urine, faeces, cerebrospinal fluid (CSF), respiratory fluids and swabs such as those from the mouth, nasal cavity, throat, skin and genitals.
- CSF cerebrospinal fluid
- the inoculated cell culture is then incubated and the cells examined for cytopathic effects induced by the virus.
- the virus can be identified on the basis of the cell type in which it either induces a cytopathic effect (CPE) or does not induce a cytopathic effect.
- CPE cytopathic effect
- the conventional (or traditional-drum) method utilizes screw cap tubes which are seeded with appropriate cell lines. After the cells reach about 80% confluency the tube is inoculated with an appropriate specimen and monitored for CPE for up to three weeks. Daily monitoring of CPE is required for the first week. Less frequent monitoring is necessary for the second and third weeks. Often, blind passage is required to enhance virus recovery.
- results obtained by the conventional tube method are predominantly based on CPE detection and are not routinely confirmed by any other method, inaccurate diagnosis can occur.
- Another limitation of the conventional tube method is that it is difficult to use more than 2 or 3 tubes per specimen due to the resulting accumulation of tubes. For example, 40 specimens per day would create 500 tubes to analyse in the first week alone.
- the shell vial method is currently the most advanced method utilized by those in the art for virus recovery.
- This method employs the use of a 5 ml plastic vial (shell vial), 16 mm in diameter which has a translucent lid. Following an appropriate treatment, a round (13 mm) coverslip is inserted into the vial. The vial is then seeded with a sensitive cell line which grows a monolayer on the cover slip. When the cell monolayer reaches about 80-90% confluency, the medium is discarded, the monolayer inoculated with the patient's specimen and the vial incubated. Then, the incubated vial is monitored for CPE, followed by the removal of the cover slip. The slip can then be fixed to a microscope slide and stained with monoclonal antibodies.
- the advantage of the shell vial method is that virus recovery can be enhanced by centrifugation of vials after inoculation which can shorten the length of time taken to obtain results to as little as 2-3 days. Further, using the shell vial method there is no need to wait for visible CPE.
- the cover slip can be removed on the second or third day and stained with appropriate monoclonal antibodies and results confirmed using antibody-antigen staining.
- the shell vial method also has a number of disadvantages. It is time consuming as the cover slips require special treatment; such as multiple washings with detergent and acetone followed by washing in distilled water and sterilisation. The cover slips also have to be manually inserted into the vials. Further, if immunofluorescent staining is necessary, the procedure becomes even more complicated and time consuming. The medium from the shell vial has to be discarded and the cover slip manually removed using specific forceps, air-dried and fixed to a microscope slide, using vacuum grease. The removal of cover slips is tedious, since the cover slips may be broken by rough manipulation or unintentionally turned and fixed to the microscope slide with the monolayer upside down.
- the 96 well plate method is another method which is used only in limited cases for recovery of viruses which grow on the same cell line. For example, if the wells are seeded with LLC-MK2 cell line the recovery of parainfluenza and also influenza viruses is possible.
- the 96 well plate method has advantages in that it is relatively easy to inoculate seeded cell lines with a particular specimen. Further, a large number of specimens can be inoculated onto the same plate and enhancement by centrifugation is also possible. Still further, the 96 well plate method only utilises a small amount of media (0.3 ml instead of 1-1.5 ml used in the shell vial method), antigen-antibody techniques may be used for confirmation of results and the method also enables easy to “read” monitoring of CPE.
- the 96 well plate method also has its disadvantages.
- the whole plate must be used for antigen-antibody detection which is not generally practical and the entire plate has to be used on the same day, even when the number of specimens is smaller than required for the whole plate. This means that for each day a new set of different plates must be used. This disadvantageously results in a situation where, once the detection is completed, there are no remaining cells available for a repeat procedure in case of an error or after a prolonged incubation period. Further, commonly only one or two different cell lines can be used per plate and the same type of specimen inoculated onto the plate.
- Flat-based wells are known to provide certain advantages when used in the context of diagnostic assays. In particular, they provide for more precise analysis compared with, say, round or curved-based wells.
- simple flat-based wells also have a disadvantage in that a meniscus tends to form in the base of the well resulting in uneven distribution of solution across the base of the well.
- the inventor has developed a flat-based well that alleviates this problem as described below.
- the invention provides a flat-based well for use in an assay, the well comprising:
- this arrangement ensures that a liquid sample placed in the sub-chamber may not form a meniscus up the side-walls of the main chamber. Rather, a liquid sample placed in the sub-chamber may retain a convex surface extending from the sub-chamber towards and/or into the main chamber. The arrangement also ensures that the base surface on which any liquid sample rests is flat, providing for more precise analysis as previously described above.
- the invention provides a well unit, comprising one or more of single flat-based wells in accordance with the invention.
- the invention provides a method of performing an assay, said method comprising using a single flat-based well in accordance with the invention or using a well unit in accordance with the invention.
- Yet another aspect of the invention provides a method of detecting a virus, said method comprising:
- the invention provides for use of a single flat-based well or use of a well unit in accordance with the invention, in an assay.
- Another aspect of the invention provides for use of a single flat-based well in accordance with the invention in a method of detecting a virus, said method comprising:
- the invention provides for use of a single flat-based well in accordance with the invention in a method for detecting a virus, said method comprising:
- FIG. 1 is a schematic representation which illustrates a perspective view of the well
- FIG. 2 is a schematic representation which illustrates a sectional side view of the well
- FIG. 3 is a schematic representation which illustrates a bottom view of the well.
- FIG. 4 is a schematic representation which illustrates a typical well configuration for a 12 ⁇ 8 array.
- the main chamber and sub-chamber may take any suitable form, provided that the sub-chamber extends from the chamber base of the main chamber.
- the single flat-based wells may take any suitable form, provided that the base of the well that receives the specimen is flat.
- the wells may have a circular, square, triangular or hexagonal cross section.
- the wells may be uniform in cross section along their height.
- the wells may taper towards their top or their bottom end. It will be appreciated that the wells will be formed using standard materials as used for conventional micro titre tray assemblies and by standard techniques.
- the main chamber has a square cross section and the sub-chamber has a circular cross section.
- the arc of the circular side of the sub-chamber in this embodiment, preferably extends to the edge of each side of the main chamber.
- the sub-chamber can hold a predetermined volume of about 30 ⁇ l in total, such that in the sub-chamber a liquid sample forms a droplet advantageously having a convex surface extending from the sub-chamber opening and further, such that the depth of the liquid is substantially constant through the sub-chamber, thus alleviating the disadvantage of a liquid sample that is placed in a well and forms a meniscus up the side walls of the well.
- the ratio of the height of the main chamber as compared to the sub-chamber is 10:1 and the ratio of the width of the main chamber as compared to the sub-chamber is between 2:1 and 1:1.
- the height of the well is 11 mm, including a 10 mm height for the main chamber and a 1 mm depth for the sub-chamber.
- the width of the well is generally 8 mm, and has a wall thickness of about 1 mm and the internal width of the sub-chamber is about 6 mm.
- the main chamber typically allows for a volume of about 360 ⁇ l and the sub-chamber typically allows for a volume of about 28.3 ⁇ l.
- a well unit including more than one of the wells in accordance with the invention.
- a well unit can be for example, a 96 or 48 well plate configuration or a unit as described in Australian Innovation Patent No. 2001100242.
- the wells could be provided with means for facilitating engagement with the well plate they are to be inserted into.
- the wells may be tapered as mentioned above to provide a friction fit in a receptacle of the well plate.
- the wells may be provided with a rib or an indentation or groove that cooperates with the receptacle of the plate that the well is to be inserted into.
- wells may be dislodged from the well plate during analysis or during transportation of the plate.
- the wells include some form of identification, such as colour coding or marking.
- the wells may, for example have markings that indicate their position (column and row) on the plate.
- the wells may also include a flat-base that is provided with marked divisions.
- the flat-base of each well may include a cross hair that divides the flat-base into four quarters.
- analysis of one quarter will provide data useful for the analysis of the flat-base as a whole. It will be appreciated that any number of divisions of the flat-base may be suitable for this purpose.
- the wells of the invention have an extremely wide variety of uses. Broadly speaking, the wells of the present invention are useful in assays. The skilled artisan will recognise that such assays include, but are not limited to Enzyme-linked Immunosorbent Assays (ELISA), bacterial cell culture, PCR amplification techniques, protein crystallisation techniques, anti-viral susceptibility testing and chemical and drug screening techniques. In one embodiment for example, the wells of the invention are useful for viral diagnostic assays.
- ELISA Enzyme-linked Immunosorbent Assays
- bacterial cell culture bacterial cell culture
- PCR amplification techniques protein crystallisation techniques
- anti-viral susceptibility testing and chemical and drug screening techniques.
- the wells of the invention are useful for viral diagnostic assays.
- the invention provides a method for detecting a virus said method comprising:
- the invention provides a method of performing an assay said method using one or more single flat-based wells in accordance with the invention as described herein.
- the assay is a viral diagnostic assay.
- sample media will typically be maintenance media which has been inoculated with the sample.
- single flat-based well includes within its scope a single well having any cross-sectional shape, provided that the base of the well that receives the specimen is flat.
- the use of a single flat-based well ensures that the examination for viruses, using standard techniques such as inverted fluorescence or optical microscopy, provides more accurate results, as compared with for example examination of a sample located in the base of a well having a round or slightly curved base.
- the single flat-based wells may be provided already seeded with a preselected cell line that will be determined, depending on its suitability for the growth and isolation of the particular virus or viruses to be analysed for.
- the cell line LLC-MK2 is suitable for detection of parainfluenza viruses, MDCK for influenza viruses; HEP-2 for Respiratory syncitial virus (RSV) and MRC-5 for cytomegalovirus (CMV), herpes simplex virus (HSV), Enteroviruses and Rhinoviruses.
- RSV Respiratory syncitial virus
- MRC-5 for cytomegalovirus (CMV), herpes simplex virus (HSV), Enteroviruses and Rhinoviruses.
- a skilled artisan could select the appropriate cell line for the growth and isolation of a given virus.
- the seeded single flat-based wells described herein may be provided in a form suitable for immediate use (i.e. a ready to use format), in the assay method of choice.
- a ready to use format the preselected cell line will usually be provided approximately 80-90% confluent. It will also be appreciated that the storage stability of such a preselected cell line will depend on the particular cell line provided.
- the seeded single flat-based wells may be provided in a form suitable, for long-term storage.
- the seeded flat-based wells may be provided frozen using standard techniques for the long-term preservation of cells.
- the cells could be grown to a suitable confluency in the single flat-based wells and the growth medium replaced with a suitable storage medium.
- the cells could be subjected to a cooling process and finally stored at ⁇ 70-80 degrees Celsius.
- the storage medium may or may not contain a cryopreservative.
- the cryopreservative which may be added to the storage medium is not particularly limited but may include DMSO and/or serum. A person skilled in the art would be familiar with suitable cryopreservative and their use. Not all cell lines can survive a freezing process and one skilled in the art will recognise which cell lines would be suitable and unsuitable in this regard.
- Reference to the subject flat-based well being “seeded” with a cell line should be understood as reference to the well being pre-seeded with a preselected cell line prior to being provided for use in a viral diagnostic assay.
- the seeded wells may actually be seeded subsequent to being provided for use in a viral diagnostic assay.
- the step of seeding the wells may include sub-steps of depositing the preselected cell line diluted in growth medium in the wells, incubating the cells in a CO 2 incubator until the cells reach about 80-90% confluency and replacing the growth medium with maintenance medium.
- a plurality of wells are seeded with a preselected cell line to provide an array of wells, for example a conventional 12 ⁇ 8 array for a 96 well plate, or a 6 ⁇ 8 array for a 48 well plate. Alternatively, if desired a larger array, such as a 14 ⁇ 8 array may be provided.
- the number of wells provided is not particularly limited. It will be appreciated that if such arrays are provided, different cells will generally be seeded in different columns of the array, again depending on the viruses to be detected.
- pre-seeded single flat-based wells of the invention may be provided suitably sealed to enable transportation and to prevent contamination and evaporation.
- the seal could take the form of a cover which fits over the full array of wells, such as a standard 48 or 96 well plate cover.
- the seal may take the form of a suitable cap which seals the individual well.
- the seal may be a suitable sealing membrane.
- the cover either for a plurality of wells or for a single flat-based well in accordance with the invention as described herein may contain markings to assist in use.
- the cover may contain a symbol or letter representing the cell line contained within.
- the step of inoculating the specimen to be analysed in the one or more cells is conducted in accordance with known procedures. For example, this will generally involve removing an appropriate amount of maintenance medium from each well to be inoculated, and depositing an amount, generally about 200-300 ⁇ l, of specimen supernatant into each well.
- the wells may then be centrifuged/incubated, for example at 4000 rpm at 35° C. for about 50-60 minutes depending on the type of centrifuged used.
- inoculum may be removed from the wells, for example by vacuum aspiration, and replaced with a suitable maintenance medium or virus recovery medium.
- a suitable maintenance medium or virus recovery medium This preferably includes cell culture media supplemented with a hormone and an enzyme.
- a specimen to be analysed includes sample specimens obtained from subject that may or may not be infected with a virus. Therefore the sample may contain a detectable virus or may be virus free. Suitable samples may be obtained from saliva, serum, urine, faeces, cerebrospinal fluid (CSF), respiratory fluids such as bronchial alveolar lavages and nasopharyngeal aspirates, and swabs such as those from the mouth, nasal cavity, throat, skin and genitals. The sample specimen may be prepared for use by dilution with a suitable media that is compatible with the cell line and virus.
- CSF cerebrospinal fluid
- respiratory fluids such as bronchial alveolar lavages and nasopharyngeal aspirates
- swabs such as those from the mouth, nasal cavity, throat, skin and genitals.
- the sample specimen may be prepared for use by dilution with a suitable media that is compatible with the cell line and virus.
- the subject may be any species of animal that may be infected with a virus.
- the subject may be a bird, fish or mammal.
- the subject is a mammal.
- Suitable mammals include farmed animals such as sheep, cattle, pigs, deer and the like, companion animals such as dogs, cats, rabbits, guinea pigs and the like, laboratory animals such as mice, rats, monkeys and the like, captive animals such as those kept in zoos and humans.
- Preferred mammals are humans.
- the subject may be a bird, particularly farmed birds such as chickens and turkeys. Specific pre-treatment methods of specimens to obtain samples suitable for virus detection are well known by the skilled artisan but may include, without being limited to, sonication and centrifugation.
- virus recovery medium refers to a medium or media which is used for virus growth and isolation.
- virus recovery medium includes maintenance medium. It has been found by the present inventor that a cell culture media which is dosed with both hormone and enzyme advantageously optimises virus recovery by maintaining cell line sensitivity at its maximum as well as aiding in the attachment of viruses to the cell wall and in some cases reducing the time taken to obtain a result.
- the enzyme added to the cell culture medium is not limited and a person skilled in the art could identify suitable enzymes.
- the term “enzyme” refers to a proteolytic enzyme.
- the enzyme is preferably a serine or aspartate protease.
- Exemplary enzymes include trypsin, chymotrypsin or pepsin.
- the enzyme is trypsin.
- hormone added to the cell culture medium is not limited and a person skilled in the art could identify suitable hormones.
- the term “hormone” refers to corticosteroids, preferably, a glucocorticoid. More preferably, the hormone is selected from dexamethasone, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, betamethasone, triamcinolone, beclomethasone, fludrocortisone acetate, deoxycorticosterone acetate (DOCA), and aldosterone. In a preferred embodiment, the hormone is dexamethasone. The hormone may be either synthetic or naturally occurring.
- DMSO dimethylsulfoxide
- DEAE diextran
- the amount of the enzyme added to the culture medium is preferably within the range 1-5 ⁇ g/ml, and preferably about 2.5 ⁇ g/ml.
- the concentration of hormone in the culture medium is preferably within the range 10 ⁇ 4 M-10 ⁇ 6 M and preferably about 10 ⁇ 6 M.
- dexamethasone and trypsin which are preferred, it has been found that a cell culture media supplemented with about 2.5 ⁇ g/ml trypsin and dexamethasone at a concentration of about 10 ⁇ 6 M gives the optimum result.
- a specific embodiment of the method of the invention employs a virus recovery medium that includes a cell culture media supplemented with 2.51 ⁇ g/ml trypsin and dexamethasone at a concentration of 10 ⁇ 5 M.
- the cell culture media which may be used in accordance with the invention is not particularly limited.
- these may include medium-199, DMEM, RPMI-1640 or MEM-EAGLE.
- MEM-EAGLE As will be readily recognised, however there is a wide variety of different media which can support the growth of cells and which are readily available to the skilled artisan.
- the cell culture media is MEM-EAGLE.
- the cell culture media may be supplemented with additives that support cell and virus growth and such additives are known to those skilled in the art. It is known that particular cell lines and/or viruses may require specific additives for optimal growth and viability.
- additives include L-glutamine, amino acids, antibiotics, serum, Hanks balanced salts, sugars such as D-glucose, inorganic salts, vitamins, phenyl red, buffers such as HEPES and surfactants such as Tween 80.
- the Virus recovery medium described above may be used in conventional diagnostic procedures for identifying viruses such as the conventional tube method and the shell vial method. Alternatively, the virus recovery medium may be used in the method of the invention as described herein.
- the virus recovery medium used in the method of the invention may be used for the recovery of a number of different viruses which are suitable for cell culture.
- viruses include, but are not limited to, the respiratory viruses, Parainfluenza 1,2,3,4 (PI 1,2,3,4), Influenza A,B (Inf A,B), Respiratory syncitial virus (RSV), Adenovirus (AD), Rhinovirus (RH), Cytomegalovirus (CMV), and viruses from the Enterovirus group (ENT) consisting of Echovirus, Coxakievirus, Enterovirus and Poliovirus, and also non-respiratory viruses such as, but not limited to, Herpes simplex virus (HSV) 1,2, Varicella zoster virus (VZV), Rubella, mumps, measles, rotavirus and polyomavirus.
- HSV Herpes simplex virus
- VZV Varicella zoster virus
- Rubella mumps, measles, rotavirus and polyomavirus.
- the inoculated cells may be incubated with the specimen to be analysed using known conditions.
- the inoculated cells may be incubated at 37° C. for a period that results in the infection of the cells with the virus, such as 45 to 90 minutes, especially 60 minutes. Incubation may be performed in an incubator or may be performed with centrifugation.
- the virus may be detected using common detection methods known in the art such as immunodetection techniques such as immunofluorescence, staining, visualisation of CPE, commonly used molecular techniques such as polymerase chain reaction (PCR), reverse transcriptase PCR(RT-PCR) and nucleic acid sequence based amplification (NASBA).
- immunodetection techniques such as immunofluorescence, staining, visualisation of CPE
- molecular techniques such as polymerase chain reaction (PCR), reverse transcriptase PCR(RT-PCR) and nucleic acid sequence based amplification (NASBA).
- washing steps are generally employed in accordance with conventional methodology.
- maintenance medium is generally removed and the cells are air dried in the wells.
- the wells may then be filled with, for example a cold methanol-acetone mixture (1:2 ratio) and fixed for 15 minutes at ⁇ 25° C. After the mixture is removed, the wells may again be air dried.
- Specific monoclonal antibodies may then be added to each of the wells, depending on the virus to be detected, and the wells incubated as needed. The monoclonal antibodies may then be discarded and the wells again washed. This process may be repeated with secondary antibodies.
- a particularly preferred embodiment of the flat-based well 10 to be used in accordance with the invention includes a main chamber 11 that is square in cross section, and a sub-chamber 12 that is circular in cross section.
- the sub-chamber 12 extends from a chamber base 13 of the main chamber 11 .
- the opening 14 of the sub-chamber is defined by the chamber base 13 of the main chamber.
- the arc of the outer wall 15 of the sub-chamber 12 extends to the outer sides of each wall 16 of the main chamber 11 (best illustrated in FIG. 3 ).
- One wall 16 of the main chamber 11 includes a groove 17 for receiving a cooperating portion of a well plate (not shown) into which the well 10 is to be placed. This facilitates secure locking of the well 10 in the plate and alleviates problems associated with wells 10 being dislodged from the plate.
- the sub-chamber 12 has a predetermined volume so that it receives a liquid sample and forms the liquid sample into a droplet advantageously having a convex surface extending from the sub-chamber opening 14 . This ensures that the depth of the liquid is substantially constant through the sub-chamber, as compared with a liquid sample that is placed in a well and forms a meniscus up the side walls of the well. In that case, the depth of liquid on the sides of the well where the meniscus forms will be substantially greater than that in the middle of the well where the meniscus is at its lowest point.
- the height X of the well is 11 mm, including a 10 mm height Y for the main chamber and a 1 mm depth Z for the sub-chamber.
- the well is generally 8 mm across its width W, and has a wall thickness T of about 1 mm.
- the internal width Wi is about 6 mm.
- the main chamber typically defines a volume of about 360 ⁇ l and the sub-chamber a volume of about 28.3 ⁇ l.
- FIG. 4 exemplifies one example of a typical 12 ⁇ 8 well plate configuration (i.e. 2 ⁇ 6 ⁇ 8) including a listing of viruses to be detected, relevant cell lines and removal days for each line.
- the plate is made up of 96 individual flat-based wells in accordance with the present invention.
- the plate can be seeded with different cell lines in the following order:
- a plate set up in this fashion would allow for example the selection of, without being limited to, the respiratory viruses Parainfluenza 1,2,3,4 (PI 1,2,3,4), Influenza A,B (Inf A,B) RSV, Adenovirus (AD), Rhinovirus (RH), Cytomegalovirus (CMV), and viruses from the Enterovirus group (ENT) consisting of Echovirus (Eco), Coxsackievirus (cox), Enterovirus (Ent) and Poliovirus (Polio), as well as, but not limited to, the non-respiratory viruses Herpes simplex virus (HSV) 1,2, and Varicella zoster virus (VZV).
- the respiratory viruses Parainfluenza 1,2,3,4 (PI 1,2,3,4), Influenza A,B (Inf A,B) RSV, Adenovirus (AD), Rhinovirus (RH), Cytomegalovirus (CMV), and viruses from the Enterovirus group (ENT) consisting of Echovirus (Eco), Coxsackievirus
- configuration of a 6 ⁇ 8 well plate may consist of cell lines seeded in the following order:
- viruses such as CMV, HSV 1,2, VZV, AD, and those from the Enterovirus group.
- the removal of the cell lines due to the individual nature of the wells, can be selective depending on the time schedule which is appropriate for the specific viral detection in question.
- time schedule which is appropriate for the specific viral detection in question.
- wells A 1 to A 3 are removed on day two.
- wells A 4 and A 5 are removed on day two.
- well A 11 is removed on the appropriate day (1-3).
- the specific nature of the individual wells facilitates this selective removal and viral detection.
- an appropriate number of wells of the well plate are inoculated with approximately 150-200 ⁇ l specimen per well.
- the remaining specimen is stored at ⁇ 70° C.
- the lid is then replaced on the plate and the date written over the wells inoculated in the plate.
- the plate is then weighed on a digital balance and balanced with balance plates and cards until all plates are equivalent weights (+/ ⁇ 0.5 g) and can be balanced in a centrifuge.
- the centrifuge is run at about 37° C. and 3500 rpm for a period of 60 min.
- each specimen is then aspirated from each well, and using a fresh disposable pipette for each specimen, each well is filled with the virus recovery medium BAC.
- the specimens are then incubated in a humidified environment at 37° C. in a CO 2 incubator (5%) by carefully placing the plates in the CO 2 incubator and incubating at 37° C. for up to seven days after inoculation of the last specimen.
- Immunofluorescent staining is advantageously used for detection of specific viruses in single wells, using specific monoclonal antibodies. Generally, the following procedure is followed:
- the medium is removed from the appropriate well(s) and the wells removed from the plate using special forceps and transferred into a different holder. These are then air dried for 3 minutes. 300 ⁇ l of a mixture of cold acetone and methanol (2:1) is then added to each well and allowed to fix for 15 minutes at ⁇ 20° C. The fixative is then discarded and the sample again air dried for 2-3 minutes. A specific monoclonal antibody (primary) is then added to each well and the cover plate put in place and the samples incubated for 30 minutes at 37° C. The samples are then removed from the incubator and each well filled with Phosphate Buffered Saline (PBS). The PBS is then discarded. This process is repeated four more times.
- PBS Phosphate Buffered Saline
- the sample is air dried for 3 minutes, after which a secondary antibody specific for the primary antibody is added to each well. Following this, incubation of the sample again takes place followed by repeated treatments with PBS as mentioned above and a final wash with double distilled water. A small amount (1 drop) of a specially prepared mounting medium is then added and the results observed under fluorescent microscope.
- One step immunofluorescent staining may also be employed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Clinical Laboratory Science (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Sustainable Development (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The present invention relates to a single flat-based well suitable for use in a viral diagnostic method. More particularly, the well has a planar or flat base, as opposed to a curved base. The invention also relates to a viral diagnostic method that employs such single wells. In an embodiment of this method a specially developed tissue culture medium supplemented with hormones and enzymes is employed.
Description
- The present invention relates to a single flat-based well suitable for use in a viral diagnostic method. More particularly, the well has a planar or flat base, as opposed to a curved base. The invention also relates to a viral diagnostic method that employs such single wells. In an embodiment of this method a specially developed tissue culture medium supplemented with hormones and enzymes is employed.
- Conventional diagnostic procedures for identifying viruses include seeding containers with particular cell lines selected on their sensitivity to certain viruses and then inoculating the cell culture with a biological sample putatively containing a virus. Such biological samples include among other things saliva, urine, faeces, cerebrospinal fluid (CSF), respiratory fluids and swabs such as those from the mouth, nasal cavity, throat, skin and genitals. The inoculated cell culture is then incubated and the cells examined for cytopathic effects induced by the virus. As certain viruses only grow on certain cells, the virus can be identified on the basis of the cell type in which it either induces a cytopathic effect (CPE) or does not induce a cytopathic effect.
- There are a number of alternative protocols to this procedure including subjecting cells which have been inoculated with a virus preparation by trypsonisation to remove the cells, followed by virus detection using monoclonal antibodies specific for viral-derived polypeptides which are labelled with a reporter molecule such as a fluorescein (FITC) molecule. A further alternative is to include a cover slip within a culture tube in order to enhance recovery of the cells.
- The conventional (or traditional-drum) method utilizes screw cap tubes which are seeded with appropriate cell lines. After the cells reach about 80% confluency the tube is inoculated with an appropriate specimen and monitored for CPE for up to three weeks. Daily monitoring of CPE is required for the first week. Less frequent monitoring is necessary for the second and third weeks. Often, blind passage is required to enhance virus recovery.
- One of the disadvantages of this method is that it is time and labour intensive because daily monitoring of the tubes is required. Generally, two people inspect the same tube for CPE by light microscope to avoid subjectivity. In addition, not all viruses cause a visible CPE and those which do not are unable to be detected by this method. Furthermore, CPE formation monitored in the conventional tube method is highly dependent on the sensitivity of the cell lines and the capability of the virus to produce visible CPE. Toxicity of the specimen may also disadvantageously produce changes similar to viral CPE giving a false result. Also, some viruses produce CPE only after a long period of time (for example, Cytomagalovirus (CMV)). Thus, as results obtained by the conventional tube method are predominantly based on CPE detection and are not routinely confirmed by any other method, inaccurate diagnosis can occur. Another limitation of the conventional tube method is that it is difficult to use more than 2 or 3 tubes per specimen due to the resulting accumulation of tubes. For example, 40 specimens per day would create 500 tubes to analyse in the first week alone.
- The shell vial method is currently the most advanced method utilized by those in the art for virus recovery. This method employs the use of a 5 ml plastic vial (shell vial), 16 mm in diameter which has a translucent lid. Following an appropriate treatment, a round (13 mm) coverslip is inserted into the vial. The vial is then seeded with a sensitive cell line which grows a monolayer on the cover slip. When the cell monolayer reaches about 80-90% confluency, the medium is discarded, the monolayer inoculated with the patient's specimen and the vial incubated. Then, the incubated vial is monitored for CPE, followed by the removal of the cover slip. The slip can then be fixed to a microscope slide and stained with monoclonal antibodies.
- The advantage of the shell vial method is that virus recovery can be enhanced by centrifugation of vials after inoculation which can shorten the length of time taken to obtain results to as little as 2-3 days. Further, using the shell vial method there is no need to wait for visible CPE. The cover slip can be removed on the second or third day and stained with appropriate monoclonal antibodies and results confirmed using antibody-antigen staining.
- However, the shell vial method also has a number of disadvantages. It is time consuming as the cover slips require special treatment; such as multiple washings with detergent and acetone followed by washing in distilled water and sterilisation. The cover slips also have to be manually inserted into the vials. Further, if immunofluorescent staining is necessary, the procedure becomes even more complicated and time consuming. The medium from the shell vial has to be discarded and the cover slip manually removed using specific forceps, air-dried and fixed to a microscope slide, using vacuum grease. The removal of cover slips is tedious, since the cover slips may be broken by rough manipulation or unintentionally turned and fixed to the microscope slide with the monolayer upside down. Another complication may arise if the seeded cells also grow on the bottom of the cover slip, thus causing the cover slip to fix to the vial and making removal of the cover slip very difficult. Practically, as for the conventional tube method, using the shell vial method it is impossible to use more than 2 or 3 tubes per specimen due to the accumulation of tubes (i.e. 40 specimens per day creates 500 shell vials per week). Further, a large amount of monoclonal antibodies is required for immunofluorescence staining in order to cover the
round 13 mm cover slip. - The 96 well plate method is another method which is used only in limited cases for recovery of viruses which grow on the same cell line. For example, if the wells are seeded with LLC-MK2 cell line the recovery of parainfluenza and also influenza viruses is possible. The 96 well plate method has advantages in that it is relatively easy to inoculate seeded cell lines with a particular specimen. Further, a large number of specimens can be inoculated onto the same plate and enhancement by centrifugation is also possible. Still further, the 96 well plate method only utilises a small amount of media (0.3 ml instead of 1-1.5 ml used in the shell vial method), antigen-antibody techniques may be used for confirmation of results and the method also enables easy to “read” monitoring of CPE.
- However, the 96 well plate method also has its disadvantages. The whole plate must be used for antigen-antibody detection which is not generally practical and the entire plate has to be used on the same day, even when the number of specimens is smaller than required for the whole plate. This means that for each day a new set of different plates must be used. This disadvantageously results in a situation where, once the detection is completed, there are no remaining cells available for a repeat procedure in case of an error or after a prolonged incubation period. Further, commonly only one or two different cell lines can be used per plate and the same type of specimen inoculated onto the plate.
- Single well methodology, as described in Australian Innovation Patent No. 2001100242, alleviates problems associated with the conventional methods described above and provides an alternative, effective and economical process for conducting viral diagnosis. The disclosure of that patent is incorporated herein in its entirety by reference.
- Flat-based wells are known to provide certain advantages when used in the context of diagnostic assays. In particular, they provide for more precise analysis compared with, say, round or curved-based wells. However, simple flat-based wells also have a disadvantage in that a meniscus tends to form in the base of the well resulting in uneven distribution of solution across the base of the well. In light of this, the inventor has developed a flat-based well that alleviates this problem as described below.
- Accordingly, in a first aspect the invention provides a flat-based well for use in an assay, the well comprising:
-
- a main chamber having an opening to receive a liquid sample, side walls extending from the opening and a chamber base; and
- a sub-chamber extending from the chamber base of the main chamber and being adapted to receive a predetermined amount of the liquid sample, wherein the sub-chamber has a flat base.
- Advantageously, this arrangement ensures that a liquid sample placed in the sub-chamber may not form a meniscus up the side-walls of the main chamber. Rather, a liquid sample placed in the sub-chamber may retain a convex surface extending from the sub-chamber towards and/or into the main chamber. The arrangement also ensures that the base surface on which any liquid sample rests is flat, providing for more precise analysis as previously described above.
- In another embodiment the invention provides a well unit, comprising one or more of single flat-based wells in accordance with the invention.
- In a further embodiment the invention provides a method of performing an assay, said method comprising using a single flat-based well in accordance with the invention or using a well unit in accordance with the invention.
- Yet another aspect of the invention provides a method of detecting a virus, said method comprising:
-
- providing one or more single flat-based wells in accordance with the invention as described herein seeded with a preselected cell line;
- inoculating a specimen to be analysed in the one or more wells; and
- examining for one or more preselected viruses in the one or more wells.
- In a further embodiment the invention provides a method for detecting a virus said method comprising:
-
- providing a single flat based well in accordance with the invention as described herein seeded with a cell line suitable for virus inoculation;
- specific pre-treatment of a specimen to obtain a sample that potentially contains a virus to be detected;
- inoculating the cell line with the sample;
- incubating the inoculated cell line;
- replacing sample media of the inoculated cell line with a virus recovery media comprising a cell culture medium supplemented with at least one hormone and at least one enzyme;
- incubating the inoculated cell line; and
- analysing the incubated cell line for the presence of a virus.
- In yet another embodiment the invention provides for use of a single flat-based well or use of a well unit in accordance with the invention, in an assay.
- Another aspect of the invention provides for use of a single flat-based well in accordance with the invention in a method of detecting a virus, said method comprising:
-
- providing one or more single flat-based wells in accordance with the invention as described herein seeded with a preselected cell line;
- inoculating a specimen to be analysed in the one or more wells; and
- examining for one or more preselected viruses in the one or more wells.
- In a further embodiment the invention provides for use of a single flat-based well in accordance with the invention in a method for detecting a virus, said method comprising:
-
- providing a single flat based well in accordance with the invention as described herein seeded with a cell line suitable for virus inoculation;
- specific pre-treatment of a specimen to obtain a sample that potentially contains a virus to be detected; inoculating the cell line with the sample;
- incubating the inoculated cell line;
- replacing sample media with a virus recovery media comprising a cell culture medium supplemented with at least one hormone and at least one enzyme;
- incubating the inoculated cell line; and
- analysing the incubated cell line for the presence of a virus.
- Embodiments of the present invention are illustrated in the accompanying non-limiting drawings in which:
-
FIG. 1 is a schematic representation which illustrates a perspective view of the well; -
FIG. 2 is a schematic representation which illustrates a sectional side view of the well; -
FIG. 3 is a schematic representation which illustrates a bottom view of the well; and -
FIG. 4 is a schematic representation which illustrates a typical well configuration for a 12×8 array. - The main chamber and sub-chamber may take any suitable form, provided that the sub-chamber extends from the chamber base of the main chamber. The single flat-based wells may take any suitable form, provided that the base of the well that receives the specimen is flat. For example, the wells may have a circular, square, triangular or hexagonal cross section. Also, the wells may be uniform in cross section along their height. Alternatively, the wells may taper towards their top or their bottom end. It will be appreciated that the wells will be formed using standard materials as used for conventional micro titre tray assemblies and by standard techniques.
- Preferably, the main chamber has a square cross section and the sub-chamber has a circular cross section. The arc of the circular side of the sub-chamber, in this embodiment, preferably extends to the edge of each side of the main chamber. This will be appreciated from the accompanying figures which better illustrate this feature.
- Typically the sub-chamber can hold a predetermined volume of about 30 μl in total, such that in the sub-chamber a liquid sample forms a droplet advantageously having a convex surface extending from the sub-chamber opening and further, such that the depth of the liquid is substantially constant through the sub-chamber, thus alleviating the disadvantage of a liquid sample that is placed in a well and forms a meniscus up the side walls of the well.
- Preferably the ratio of the height of the main chamber as compared to the sub-chamber is 10:1 and the ratio of the width of the main chamber as compared to the sub-chamber is between 2:1 and 1:1. In a preferred embodiment, the height of the well is 11 mm, including a 10 mm height for the main chamber and a 1 mm depth for the sub-chamber. The width of the well is generally 8 mm, and has a wall thickness of about 1 mm and the internal width of the sub-chamber is about 6 mm. Thus the main chamber typically allows for a volume of about 360 μl and the sub-chamber typically allows for a volume of about 28.3 μl.
- This particular embodiment may equally provide advantages if the wells are used in a well unit. For example, where a number of the wells are joined and not used individually. Thus, according to an alternative embodiment of the invention there is provided a well unit including more than one of the wells in accordance with the invention. A well unit can be for example, a 96 or 48 well plate configuration or a unit as described in Australian Innovation Patent No. 2001100242.
- It will be appreciated by one skilled in the art that in the context of some assay methods where the wells are required to be inserted into a plate that the wells could be provided with means for facilitating engagement with the well plate they are to be inserted into. For example, the wells may be tapered as mentioned above to provide a friction fit in a receptacle of the well plate. Alternatively, the wells may be provided with a rib or an indentation or groove that cooperates with the receptacle of the plate that the well is to be inserted into.
- In some instances, wells may be dislodged from the well plate during analysis or during transportation of the plate. As such, in a preferred embodiment the wells include some form of identification, such as colour coding or marking. The wells may, for example have markings that indicate their position (column and row) on the plate.
- To assist analysis, the wells may also include a flat-base that is provided with marked divisions. For example, the flat-base of each well may include a cross hair that divides the flat-base into four quarters. Thus, analysis of one quarter will provide data useful for the analysis of the flat-base as a whole. It will be appreciated that any number of divisions of the flat-base may be suitable for this purpose.
- The wells of the invention have an extremely wide variety of uses. Broadly speaking, the wells of the present invention are useful in assays. The skilled artisan will recognise that such assays include, but are not limited to Enzyme-linked Immunosorbent Assays (ELISA), bacterial cell culture, PCR amplification techniques, protein crystallisation techniques, anti-viral susceptibility testing and chemical and drug screening techniques. In one embodiment for example, the wells of the invention are useful for viral diagnostic assays.
- As used herein, reference to an assay should be understood as reference to any conventional laboratory techniques which utilise micro titre wells.
- Accordingly, in a second aspect the invention provides a method for detecting a virus said method comprising:
-
- providing one or more single flat-based wells in accordance with the invention as described herein seeded with a preselected cell line;
- inoculating a specimen to be analysed in the one or more wells; and
- examining for one or more preselected viruses in the one or more wells.
- In one embodiment the invention provides a method of performing an assay said method using one or more single flat-based wells in accordance with the invention as described herein. Preferably the assay is a viral diagnostic assay.
- In a further embodiment the invention provides a method for detecting a virus said method comprising:
-
- providing a single flat based well in accordance with the invention as described herein seeded with a cell line suitable for virus inoculation;
- specific pre-treatment of a specimen to obtain a sample that potentially contains a virus to be detected;
- inoculating the cell line with the sample;
- incubating the inoculated cell line;
- replacing sample media of the inoculated cell line with a virus recovery media comprising a cell culture medium supplemented with at least one hormone and at least one enzyme;
- incubating the inoculated cell line; and analysing the incubated cell line for the presence of a virus.
- It will be appreciated that in this method the sample media will typically be maintenance media which has been inoculated with the sample.
- As used herein, the term “single flat-based well” includes within its scope a single well having any cross-sectional shape, provided that the base of the well that receives the specimen is flat.
- In the context of the viral diagnostic aspects of the present invention the use of a single flat-based well ensures that the examination for viruses, using standard techniques such as inverted fluorescence or optical microscopy, provides more accurate results, as compared with for example examination of a sample located in the base of a well having a round or slightly curved base.
- The single flat-based wells may be provided already seeded with a preselected cell line that will be determined, depending on its suitability for the growth and isolation of the particular virus or viruses to be analysed for. For example, the cell line LLC-MK2 is suitable for detection of parainfluenza viruses, MDCK for influenza viruses; HEP-2 for Respiratory syncitial virus (RSV) and MRC-5 for cytomegalovirus (CMV), herpes simplex virus (HSV), Enteroviruses and Rhinoviruses. A skilled artisan could select the appropriate cell line for the growth and isolation of a given virus.
- It will be recognised that the seeded single flat-based wells described herein may be provided in a form suitable for immediate use (i.e. a ready to use format), in the assay method of choice. One skilled in the art will appreciate that in a ready to use format the preselected cell line will usually be provided approximately 80-90% confluent. It will also be appreciated that the storage stability of such a preselected cell line will depend on the particular cell line provided.
- Alternatively, the seeded single flat-based wells may be provided in a form suitable, for long-term storage. For example, the seeded flat-based wells may be provided frozen using standard techniques for the long-term preservation of cells. For example, but not limiting the cell freezing process in any way, the cells could be grown to a suitable confluency in the single flat-based wells and the growth medium replaced with a suitable storage medium. Following this step, the cells could be subjected to a cooling process and finally stored at −70-80 degrees Celsius. The storage medium may or may not contain a cryopreservative. The cryopreservative which may be added to the storage medium is not particularly limited but may include DMSO and/or serum. A person skilled in the art would be familiar with suitable cryopreservative and their use. Not all cell lines can survive a freezing process and one skilled in the art will recognise which cell lines would be suitable and unsuitable in this regard.
- It will be recognised that cell lines provided in a frozen format would then be subjected to an appropriate thawing process and the storage medium replaced with virus recovery medium. It will be appreciated by one skilled in the art that once thawed the cells would then usually be grown to 80-90% confluency before being used in the method of the invention as described herein.
- Reference to the subject flat-based well being “seeded” with a cell line should be understood as reference to the well being pre-seeded with a preselected cell line prior to being provided for use in a viral diagnostic assay. Alternatively, the seeded wells may actually be seeded subsequent to being provided for use in a viral diagnostic assay. The step of seeding the wells may include sub-steps of depositing the preselected cell line diluted in growth medium in the wells, incubating the cells in a CO2 incubator until the cells reach about 80-90% confluency and replacing the growth medium with maintenance medium.
- It will be appreciated that, when multiple wells are to be compared directly for the growth and isolation of a particular virus, the volume of media in each well should be identical.
- In certain embodiments, a plurality of wells are seeded with a preselected cell line to provide an array of wells, for example a conventional 12×8 array for a 96 well plate, or a 6×8 array for a 48 well plate. Alternatively, if desired a larger array, such as a 14×8 array may be provided. The number of wells provided is not particularly limited. It will be appreciated that if such arrays are provided, different cells will generally be seeded in different columns of the array, again depending on the viruses to be detected.
- It will be appreciated that pre-seeded single flat-based wells of the invention may be provided suitably sealed to enable transportation and to prevent contamination and evaporation. For example, in the case of a plurality of wells the seal could take the form of a cover which fits over the full array of wells, such as a standard 48 or 96 well plate cover. Alternatively, in the case of a single flat-based well, the seal may take the form of a suitable cap which seals the individual well. In another alternative, the seal may be a suitable sealing membrane.
- It will also be appreciated that the cover either for a plurality of wells or for a single flat-based well in accordance with the invention as described herein may contain markings to assist in use. For example, the cover may contain a symbol or letter representing the cell line contained within.
- The step of inoculating the specimen to be analysed in the one or more cells is conducted in accordance with known procedures. For example, this will generally involve removing an appropriate amount of maintenance medium from each well to be inoculated, and depositing an amount, generally about 200-300 μl, of specimen supernatant into each well. The wells may then be centrifuged/incubated, for example at 4000 rpm at 35° C. for about 50-60 minutes depending on the type of centrifuged used.
- After being removed from the centrifuge, inoculum may be removed from the wells, for example by vacuum aspiration, and replaced with a suitable maintenance medium or virus recovery medium. This preferably includes cell culture media supplemented with a hormone and an enzyme.
- As used herein, the term “a specimen to be analysed” includes sample specimens obtained from subject that may or may not be infected with a virus. Therefore the sample may contain a detectable virus or may be virus free. Suitable samples may be obtained from saliva, serum, urine, faeces, cerebrospinal fluid (CSF), respiratory fluids such as bronchial alveolar lavages and nasopharyngeal aspirates, and swabs such as those from the mouth, nasal cavity, throat, skin and genitals. The sample specimen may be prepared for use by dilution with a suitable media that is compatible with the cell line and virus.
- The subject may be any species of animal that may be infected with a virus. For example, the subject may be a bird, fish or mammal. In some embodiments, the subject is a mammal. Suitable mammals include farmed animals such as sheep, cattle, pigs, deer and the like, companion animals such as dogs, cats, rabbits, guinea pigs and the like, laboratory animals such as mice, rats, monkeys and the like, captive animals such as those kept in zoos and humans. Preferred mammals are humans. In other embodiments, the subject may be a bird, particularly farmed birds such as chickens and turkeys. Specific pre-treatment methods of specimens to obtain samples suitable for virus detection are well known by the skilled artisan but may include, without being limited to, sonication and centrifugation.
- As used herein, the terms “virus recovery medium” or “virus recovery media” refers to a medium or media which is used for virus growth and isolation. For example, virus recovery medium includes maintenance medium. It has been found by the present inventor that a cell culture media which is dosed with both hormone and enzyme advantageously optimises virus recovery by maintaining cell line sensitivity at its maximum as well as aiding in the attachment of viruses to the cell wall and in some cases reducing the time taken to obtain a result.
- The enzyme added to the cell culture medium is not limited and a person skilled in the art could identify suitable enzymes. In some embodiments, the term “enzyme” refers to a proteolytic enzyme. In these embodiments, the enzyme is preferably a serine or aspartate protease. Exemplary enzymes include trypsin, chymotrypsin or pepsin. In preferred embodiments, the enzyme is trypsin.
- The hormone added to the cell culture medium is not limited and a person skilled in the art could identify suitable hormones. In some embodiments, the term “hormone” refers to corticosteroids, preferably, a glucocorticoid. More preferably, the hormone is selected from dexamethasone, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, betamethasone, triamcinolone, beclomethasone, fludrocortisone acetate, deoxycorticosterone acetate (DOCA), and aldosterone. In a preferred embodiment, the hormone is dexamethasone. The hormone may be either synthetic or naturally occurring.
- While the combination of hormone and enzyme is the most preferred embodiment, alternatively it has been found that DMSO (dimethylsulfoxide) and DEAE (dextran) may also be useful.
- The amount of the enzyme added to the culture medium is preferably within the range 1-5 μg/ml, and preferably about 2.5 μg/ml. The concentration of hormone in the culture medium is preferably within the range 10−4M-10−6M and preferably about 10−6M. However, in the case of dexamethasone and trypsin, which are preferred, it has been found that a cell culture media supplemented with about 2.5 μg/ml trypsin and dexamethasone at a concentration of about 10−6M gives the optimum result.
- Accordingly, a specific embodiment of the method of the invention employs a virus recovery medium that includes a cell culture media supplemented with 2.51 μg/ml trypsin and dexamethasone at a concentration of 10−5M.
- The cell culture media which may be used in accordance with the invention is not particularly limited. For example, these may include medium-199, DMEM, RPMI-1640 or MEM-EAGLE. As will be readily recognised, however there is a wide variety of different media which can support the growth of cells and which are readily available to the skilled artisan. However, according to a preferred embodiment the cell culture media is MEM-EAGLE.
- The cell culture media may be supplemented with additives that support cell and virus growth and such additives are known to those skilled in the art. It is known that particular cell lines and/or viruses may require specific additives for optimal growth and viability. Exemplary additives include L-glutamine, amino acids, antibiotics, serum, Hanks balanced salts, sugars such as D-glucose, inorganic salts, vitamins, phenyl red, buffers such as HEPES and surfactants such as Tween 80.
- The Virus recovery medium described above may be used in conventional diagnostic procedures for identifying viruses such as the conventional tube method and the shell vial method. Alternatively, the virus recovery medium may be used in the method of the invention as described herein.
- The virus recovery medium used in the method of the invention may be used for the recovery of a number of different viruses which are suitable for cell culture. The skilled artisan will recognise that such viruses include, but are not limited to, the respiratory viruses,
Parainfluenza 1,2,3,4 (PI 1,2,3,4), Influenza A,B (Inf A,B), Respiratory syncitial virus (RSV), Adenovirus (AD), Rhinovirus (RH), Cytomegalovirus (CMV), and viruses from the Enterovirus group (ENT) consisting of Echovirus, Coxakievirus, Enterovirus and Poliovirus, and also non-respiratory viruses such as, but not limited to, Herpes simplex virus (HSV) 1,2, Varicella zoster virus (VZV), Rubella, mumps, measles, rotavirus and polyomavirus. - In the method of the invention the inoculated cells may be incubated with the specimen to be analysed using known conditions. For example, the inoculated cells may be incubated at 37° C. for a period that results in the infection of the cells with the virus, such as 45 to 90 minutes, especially 60 minutes. Incubation may be performed in an incubator or may be performed with centrifugation.
- The virus may be detected using common detection methods known in the art such as immunodetection techniques such as immunofluorescence, staining, visualisation of CPE, commonly used molecular techniques such as polymerase chain reaction (PCR), reverse transcriptase PCR(RT-PCR) and nucleic acid sequence based amplification (NASBA).
- In order to prepare the wells for examination, a number of washing steps are generally employed in accordance with conventional methodology. For example, maintenance medium is generally removed and the cells are air dried in the wells. The wells may then be filled with, for example a cold methanol-acetone mixture (1:2 ratio) and fixed for 15 minutes at −25° C. After the mixture is removed, the wells may again be air dried. Specific monoclonal antibodies may then be added to each of the wells, depending on the virus to be detected, and the wells incubated as needed. The monoclonal antibodies may then be discarded and the wells again washed. This process may be repeated with secondary antibodies.
- After a final air drying, 1-2 drops of fluorescent mounting medium may be added to the well and the contents examined for immunofluorescence.
- Reference will now be made to the accompanying drawings which illustrate embodiments of the present invention.
- Referring to
FIG. 1 , a particularly preferred embodiment of the flat-based well 10 to be used in accordance with the invention includes amain chamber 11 that is square in cross section, and a sub-chamber 12 that is circular in cross section. The sub-chamber 12 extends from achamber base 13 of themain chamber 11. As such theopening 14 of the sub-chamber is defined by thechamber base 13 of the main chamber. The arc of theouter wall 15 of the sub-chamber 12 extends to the outer sides of eachwall 16 of the main chamber 11 (best illustrated inFIG. 3 ). - One
wall 16 of themain chamber 11 includes agroove 17 for receiving a cooperating portion of a well plate (not shown) into which thewell 10 is to be placed. This facilitates secure locking of the well 10 in the plate and alleviates problems associated withwells 10 being dislodged from the plate. - The sub-chamber 12 has a predetermined volume so that it receives a liquid sample and forms the liquid sample into a droplet advantageously having a convex surface extending from the
sub-chamber opening 14. This ensures that the depth of the liquid is substantially constant through the sub-chamber, as compared with a liquid sample that is placed in a well and forms a meniscus up the side walls of the well. In that case, the depth of liquid on the sides of the well where the meniscus forms will be substantially greater than that in the middle of the well where the meniscus is at its lowest point. - Preferably, the height X of the well is 11 mm, including a 10 mm height Y for the main chamber and a 1 mm depth Z for the sub-chamber. The well is generally 8 mm across its width W, and has a wall thickness T of about 1 mm. Thus, the internal width Wi is about 6 mm. The main chamber typically defines a volume of about 360 μl and the sub-chamber a volume of about 28.3 μl.
-
FIG. 4 exemplifies one example of a typical 12×8 well plate configuration (i.e. 2×6×8) including a listing of viruses to be detected, relevant cell lines and removal days for each line. The plate is made up of 96 individual flat-based wells in accordance with the present invention. - As will be seen from
FIG. 4 , the plate can be seeded with different cell lines in the following order: -
- Columns 1-3 LLC-MK2
-
4, 5 MDCKColumns -
Column 6 Hep2 - Column 7 A549
- Column 8 RK13
- Columns 9-12 MRC-5
- A plate set up in this fashion would allow for example the selection of, without being limited to, the
respiratory viruses Parainfluenza 1,2,3,4 (PI 1,2,3,4), Influenza A,B (Inf A,B) RSV, Adenovirus (AD), Rhinovirus (RH), Cytomegalovirus (CMV), and viruses from the Enterovirus group (ENT) consisting of Echovirus (Eco), Coxsackievirus (cox), Enterovirus (Ent) and Poliovirus (Polio), as well as, but not limited to, the non-respiratory viruses Herpes simplex virus (HSV) 1,2, and Varicella zoster virus (VZV). - In a further example, configuration of a 6×8 well plate may consist of cell lines seeded in the following order:
-
Columns 1-3 A 549 Columns 4-6 MRC-5 - This would allow for example the detection of viruses such as CMV,
HSV 1,2, VZV, AD, and those from the Enterovirus group. - Finally a configuration of 14×8 wells would ultimately allow for the detection of pathogens like
1,2,3,4; Inf A,B; RSV; AD; RH; ENT (Echo, cox, Ent, Polio);PI HSV 1,2; VZV; Rubella; Mumps; Measles; Rotavirus; Polyomavirus and also other pathogens-viruses using appropriate cell lines. - The removal of the cell lines, due to the individual nature of the wells, can be selective depending on the time schedule which is appropriate for the specific viral detection in question. In particular, if the detection of PI 1-4 is desired, taking row A for example, wells A 1 to A 3 are removed on day two. Similarly, if the detection of Inf A, B is desired, wells A 4 and A 5 are removed on day two. However, if the detection of Entero is required, then well A 11 is removed on the appropriate day (1-3). The specific nature of the individual wells facilitates this selective removal and viral detection.
- Reference will now be made to a particular procedure which may be followed using the kit of one aspect of the invention, many steps of which may be optional and should not be considered to be limiting on the invention in any way.
- Using vacuum and sterile glass pasteur pipettes, medium is aspirated from all wells to be inoculated. Disposal of pasteur pipettes in a large sharps container is advantageously facilitated.
- Using a disposable pipette, an appropriate number of wells of the well plate are inoculated with approximately 150-200 μl specimen per well. The remaining specimen is stored at −70° C. The lid is then replaced on the plate and the date written over the wells inoculated in the plate.
- The plate is then weighed on a digital balance and balanced with balance plates and cards until all plates are equivalent weights (+/−0.5 g) and can be balanced in a centrifuge. The centrifuge is run at about 37° C. and 3500 rpm for a period of 60 min. Using vacuum and sterile pasteur pipettes each specimen is then aspirated from each well, and using a fresh disposable pipette for each specimen, each well is filled with the virus recovery medium BAC.
- The specimens are then incubated in a humidified environment at 37° C. in a CO2 incubator (5%) by carefully placing the plates in the CO2 incubator and incubating at 37° C. for up to seven days after inoculation of the last specimen.
- Immunofluorescent staining is advantageously used for detection of specific viruses in single wells, using specific monoclonal antibodies. Generally, the following procedure is followed:
- Using vacuum suction, the medium is removed from the appropriate well(s) and the wells removed from the plate using special forceps and transferred into a different holder. These are then air dried for 3 minutes. 300 μl of a mixture of cold acetone and methanol (2:1) is then added to each well and allowed to fix for 15 minutes at −20° C. The fixative is then discarded and the sample again air dried for 2-3 minutes. A specific monoclonal antibody (primary) is then added to each well and the cover plate put in place and the samples incubated for 30 minutes at 37° C. The samples are then removed from the incubator and each well filled with Phosphate Buffered Saline (PBS). The PBS is then discarded. This process is repeated four more times. Again, the sample is air dried for 3 minutes, after which a secondary antibody specific for the primary antibody is added to each well. Following this, incubation of the sample again takes place followed by repeated treatments with PBS as mentioned above and a final wash with double distilled water. A small amount (1 drop) of a specially prepared mounting medium is then added and the results observed under fluorescent microscope. One step immunofluorescent staining may also be employed.
- Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers or steps.
- Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
Claims (11)
1. A method of performing an assay, said method comprising using a single flat-based well comprising:
i. a main chamber having an opening to receive a liquid sample; side walls which extend from the opening and a chamber base; and
ii. a sub-chamber extending from below the chamber base of the main chamber, the sub-chamber adapted to receive a predetermined amount of the liquid sample, wherein the sub-chamber has a flat base.
2. A method of detecting a virus according to claim 1 , said method comprising:
i. providing one or more single flat-based wells seeded with a preselected cell line
ii. inoculating a specimen to be analysed in the one or more wells; and
iii. examining for one or more preselected viruses in the one or more wells.
3. A method of detecting a virus according to claim 2 , said method comprising:
i. providing a single flat-based well seeded with a cell line suitable for virus inoculation;
ii. specific pre-treatment of a specimen to obtain a sample that potentially contains a virus to be detected;
iii. inoculating the cell line with the sample;
iv. incubating the inoculated cell line;
v. replacing sample media of the inoculated cell line with a virus recovery media comprising a cell culture medium supplemented with at least one hormone and at least one enzyme;
vi. incubating the inoculated cell line from (v); and
vii. analysing the cell line from (vi) for the presence of a virus.
4. A method of detecting a virus according to claim 2 , wherein the main chamber of the single flat-based well has a square cross section and the sub-chamber of the single flat-based well has a circular cross section.
5. A method of detecting a virus according to claim 2 , wherein the single flat-based well is provided with a means for facilitating engagement with a well plate into which the well is to be inserted.
6. A method of detecting a virus according to claim 2 , wherein the single flat-based well is tapered to provide a friction fit in a receptacle of a well plate.
7. A method of detecting a virus of claim 2 , wherein the single flat-based well is provided with a rib or an indentation or groove that cooperates with a receptacle of the well plate.
8. A method of detecting a virus according to claim 2 , wherein the well includes a form of identification.
9. A method of detecting a virus according to claim 2 , wherein the single flat-based well is provided with marked divisions adapted to assist analysis.
10. A method of detecting a virus according to claim 2 wherein the single flat-based well is seeded with a preselected cell line in a virus recovery medium, the seeded well being provided either frozen or ready to use.
11. A method of detecting a virus providing a well unit comprising more than one of the single flat-based wells according to claim 2 .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/947,181 US20110065096A1 (en) | 2005-03-10 | 2010-11-16 | Viral diagnostic method and well for use in same |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005901141A AU2005901141A0 (en) | 2005-03-10 | Viral diagnostic method and well for use in same | |
| AU2005901141 | 2005-03-10 | ||
| PCT/AU2006/000325 WO2006094364A1 (en) | 2005-03-10 | 2006-03-10 | Viral diagnostic method and well for use in same |
| US90810107A | 2007-09-13 | 2007-09-13 | |
| US12/947,181 US20110065096A1 (en) | 2005-03-10 | 2010-11-16 | Viral diagnostic method and well for use in same |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU2006/000325 Continuation WO2006094364A1 (en) | 2005-03-10 | 2006-03-10 | Viral diagnostic method and well for use in same |
| US11/908,101 Continuation US7833780B2 (en) | 2005-03-10 | 2006-03-10 | Viral diagnostic method and well for use in same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20110065096A1 true US20110065096A1 (en) | 2011-03-17 |
Family
ID=36952887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/908,101 Expired - Fee Related US7833780B2 (en) | 2005-03-10 | 2006-03-10 | Viral diagnostic method and well for use in same |
| US12/947,181 Abandoned US20110065096A1 (en) | 2005-03-10 | 2010-11-16 | Viral diagnostic method and well for use in same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/908,101 Expired - Fee Related US7833780B2 (en) | 2005-03-10 | 2006-03-10 | Viral diagnostic method and well for use in same |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7833780B2 (en) |
| EP (1) | EP1856238A4 (en) |
| JP (1) | JP2008532501A (en) |
| KR (1) | KR20070118633A (en) |
| CN (1) | CN101163787A (en) |
| AU (1) | AU2006222481B2 (en) |
| BR (1) | BRPI0607960A2 (en) |
| CA (1) | CA2600412A1 (en) |
| IL (1) | IL185797A0 (en) |
| MX (1) | MX2007010976A (en) |
| NZ (1) | NZ561759A (en) |
| RU (1) | RU2450055C2 (en) |
| WO (1) | WO2006094364A1 (en) |
| ZA (1) | ZA200708254B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833780B2 (en) * | 2005-03-10 | 2010-11-16 | Robert Alexander | Viral diagnostic method and well for use in same |
| EP2163306A1 (en) * | 2008-09-12 | 2010-03-17 | F. Hoffmann-la Roche AG | Multi-well plate with tailored chambers |
| TW201623604A (en) * | 2014-09-25 | 2016-07-01 | 住友電木股份有限公司 | Culture container |
| KR101895531B1 (en) | 2017-04-06 | 2018-09-05 | 고신대학교 산학협력단 | Test method using chemosensitivity test kit for cancer cell line |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180555A (en) * | 1988-02-16 | 1993-01-19 | Bio Merieux | Microbiological analysis cup or the like |
| US7833780B2 (en) * | 2005-03-10 | 2010-11-16 | Robert Alexander | Viral diagnostic method and well for use in same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599314A (en) * | 1983-06-14 | 1986-07-08 | Hsc Research Development Corporation | Multiple vessel specimen tray with lid for releasably adhering vessel covers |
| JPS6251977A (en) * | 1985-09-02 | 1987-03-06 | Terumo Corp | Tissue culture plate |
| JPS6269979A (en) * | 1985-09-20 | 1987-03-31 | Terumo Corp | Meniscus controlling apparatus and light transmitting type testing device equipped therewith |
| JPS6274299A (en) * | 1985-09-26 | 1987-04-06 | Yoshio Numazaki | Virus isolation plate |
| FR2627191B1 (en) * | 1988-02-16 | 1991-10-11 | Api System | MICROBIOLOGICAL OR SIMILAR ANALYSIS CUP |
| US5098661A (en) * | 1988-11-16 | 1992-03-24 | Medical Laboratory Automation, Inc. | Coded cuvette for use in testing apparatus |
| TW328526B (en) * | 1996-09-17 | 1998-03-21 | Interlego Ag | A toy building set |
| RU7874U1 (en) * | 1998-01-22 | 1998-10-16 | Товарищество с ограниченной ответственностью - Научно-производственное предприятие "Аквапаст" | DIAGNOSTIC MEANS |
| JP3766575B2 (en) * | 2000-01-18 | 2006-04-12 | オリンパス株式会社 | Analytical method and container for analysis using reactive fine particles |
| AU2001100242B4 (en) | 2000-08-08 | 2001-08-30 | Robert Alexander | Micro titre tray assembly and viral diagnostic kit including same |
| US6571525B2 (en) * | 2001-08-01 | 2003-06-03 | J. David Coleman | Construction block |
-
2006
- 2006-03-10 US US11/908,101 patent/US7833780B2/en not_active Expired - Fee Related
- 2006-03-10 AU AU2006222481A patent/AU2006222481B2/en not_active Ceased
- 2006-03-10 MX MX2007010976A patent/MX2007010976A/en active IP Right Grant
- 2006-03-10 JP JP2008500010A patent/JP2008532501A/en not_active Ceased
- 2006-03-10 BR BRPI0607960-1A patent/BRPI0607960A2/en not_active IP Right Cessation
- 2006-03-10 CA CA002600412A patent/CA2600412A1/en not_active Abandoned
- 2006-03-10 NZ NZ561759A patent/NZ561759A/en not_active IP Right Cessation
- 2006-03-10 KR KR1020077023092A patent/KR20070118633A/en not_active Ceased
- 2006-03-10 CN CNA2006800130206A patent/CN101163787A/en active Pending
- 2006-03-10 WO PCT/AU2006/000325 patent/WO2006094364A1/en not_active Ceased
- 2006-03-10 EP EP06704998A patent/EP1856238A4/en not_active Withdrawn
- 2006-03-10 RU RU2007137097/10A patent/RU2450055C2/en not_active IP Right Cessation
-
2007
- 2007-09-06 IL IL185797A patent/IL185797A0/en unknown
- 2007-09-27 ZA ZA200708254A patent/ZA200708254B/en unknown
-
2010
- 2010-11-16 US US12/947,181 patent/US20110065096A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180555A (en) * | 1988-02-16 | 1993-01-19 | Bio Merieux | Microbiological analysis cup or the like |
| US7833780B2 (en) * | 2005-03-10 | 2010-11-16 | Robert Alexander | Viral diagnostic method and well for use in same |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2600412A1 (en) | 2006-09-14 |
| AU2006222481A1 (en) | 2006-09-14 |
| EP1856238A1 (en) | 2007-11-21 |
| EP1856238A4 (en) | 2012-04-25 |
| US7833780B2 (en) | 2010-11-16 |
| BRPI0607960A2 (en) | 2009-10-27 |
| WO2006094364A1 (en) | 2006-09-14 |
| RU2007137097A (en) | 2009-04-20 |
| CN101163787A (en) | 2008-04-16 |
| ZA200708254B (en) | 2008-10-29 |
| US20080166702A1 (en) | 2008-07-10 |
| NZ561759A (en) | 2010-08-27 |
| JP2008532501A (en) | 2008-08-21 |
| AU2006222481B2 (en) | 2012-06-28 |
| RU2450055C2 (en) | 2012-05-10 |
| KR20070118633A (en) | 2007-12-17 |
| MX2007010976A (en) | 2008-03-10 |
| IL185797A0 (en) | 2008-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007203372B2 (en) | Universal collection medium | |
| US6969585B2 (en) | Universal collection medium | |
| Dilnessa et al. | Cell culture, cytopathic effect and immunofluorescence diagnosis of viral infection | |
| Spackman et al. | Avian influenza virus isolation, propagation, and titration in embryonated chicken eggs | |
| US20110065096A1 (en) | Viral diagnostic method and well for use in same | |
| CN112379105A (en) | Method for detecting IPMA (ionic polymer antigen) neutralizing antibody of PRRSV (porcine reproductive and respiratory syndrome Virus) | |
| Carmina et al. | Indirect Immunoperoxidase Test (IPT) for Detection of Antibodies Against African Swine Fever Virus (ASFV) on African Green Monkey Cell Lines (Vero, MS) | |
| CN112362880A (en) | IFA (IFA neutralizing antibody) detection method for PRRSV (porcine reproductive and respiratory syndrome Virus) | |
| Killian | Avian influenza virus sample types, collection, and handling | |
| AU2006206051B2 (en) | Virus recovery medium, use thereof and viral diagnostic kit including same | |
| Origgi et al. | Isolation of pathogens | |
| US4329424A (en) | Macroscopic method for determining cytopathic effects in viral assay | |
| Selleck et al. | Avian influenza | |
| AU2001100242B4 (en) | Micro titre tray assembly and viral diagnostic kit including same | |
| Leland et al. | Virus isolation | |
| RU2247388C1 (en) | Method for express-diagnosis of whooping cough | |
| Cêtre-Sossah | Isolation of Rift Valley fever virus from field specimens using cell culture approaches | |
| Kirkland et al. | Diagnostic Techniques for Bluetongue Viruses | |
| Alexander et al. | Rapid enhanced tissue culture immunofluorescence: a new, rapid method for detection of viruses | |
| Cann et al. | Virus isolation | |
| WO1992009704A1 (en) | Method for in situ detection and identification of nucleic acid sequences | |
| UA133573U (en) | METHOD OF MICROMETHOD METHOD OF DETERMINING ACTIVITY OF NUTRITIONAL ENVIRONMENTS FOR CULTIVATION OF CELLS | |
| Smith | BVD update. | |
| UA62119A (en) | Method for determining the concentration of the transplanted calf trachea culture by a photocolorimetric analyzer | |
| LI | Problems and solutions on standardization of reagents for detection of HBV and HCV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |